6533b821fe1ef96bd127c2a8
RESEARCH PRODUCT
Sedation During Neurocritical Care
Vicent QuilisVicent QuilisFederico BilottaRafael BadenesVicente ChisbertNieves Vanaclochasubject
medicine.medical_specialtymedicine.drug_classSedationCritical Care and Intensive Care Medicinelcsh:RD78.3-87.303 medical and health sciences0302 clinical medicine030202 anesthesiologymedicineKetamineDexmedetomidineIntensive care medicinebusiness.industryNeurointensive careneurointensive care unitReview articleneurological wakeup testAnesthesiology and Pain Medicineneurocritical carelcsh:AnesthesiologySedativesedative agentsMidazolamNeurology (clinical)medicine.symptombusinessPropofol030217 neurology & neurosurgerymedicine.drugdescription
AbstractSedation is an essential therapeutic strategy in the care of neurocritical patients. Intravenous sedative agents are the most widely used, with promising alternatives (dexmedetomidine, ketamine, and volatile agents) to propofol and midazolam arising. Studies designed to evaluate superiority and avoid biases are required. A neurological awakening test is safe in most patients. Potential risks and benefits of limiting deep sedation and daily interruption of sedation in these patients remain unclear. The aim of this review was to report recent clinical evidence on sedation in this subgroup of patients, focusing on its effects on clinical prognosis.
year | journal | country | edition | language |
---|---|---|---|---|
2019-06-01 | Journal of Neuroanaesthesiology and Critical Care |